

Special Issue

Genome Sequencing and Genetic Testing for Cancer

Message from the Guest Editor

The landscape of oncology has been fundamentally transformed by the integration of Next-Generation Sequencing (NGS) and comprehensive genetic profiling. These advancements allow for a deeper understanding of tumor heterogeneity and the molecular drivers of malignancy.

This Special Issue, “Genome Sequencing and Genetic Testing for Cancer”, aims to explore the pivotal role of genomic data in refining diagnosis, predicting therapeutic response, and monitoring disease progression. We seek original research and comprehensive reviews that delve into the clinical utility of liquid biopsies, the identification of novel biomarkers, and the implementation of whole-genome sequencing in routine clinical practice. Furthermore, we encourage submissions focusing on the integration of multi-omics data and artificial intelligence in interpreting complex genetic variants. By bridging the gap between benchside discovery and bedside application, this Special Issue intends to highlight how genetic testing is steering the future of precision oncology and improving patient outcomes globally.

Guest Editor

Dr. Kapila Gunasekera

Department of Chemistry, Biochemistry and Pharmaceutical Sciences,
University of Bern, Bern, Switzerland

Deadline for manuscript submissions

10 October 2026

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/270160

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))